Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Explore the Intriguing Ideas in the Arena of Vaccines.
- Vaccines Congress 2018

About

Allied Academies every year hosts interdisciplinary international conferences worldwide on cutting-edge basic and applied research in life sciences, Pharma, medicine, healthcare and nursing delivered by the best talents in industry and academia. Our conferences are oriented to drive the scientific community at large, facilitating access to the newest technical and scientific achievements and to shape future research directions through the publication of applied and theoretical research findings of the highest quality.

Allied Academies invites all the participants from all across the globe to attend "World Vaccine and Immunology Congress”, on July 23-24, 2018 in Osaka, Japan which includes prompt keynote presentations, poster presentations, oral talks, and exhibitions.

Vaccines Congress 2018 aims to unite the Professors, researchers, business mammoths, and technocrats to give a global gathering to the spread of unique research comes about, new thoughts and viable improvement and find progresses in the field of Vaccine, Immunization and Vaccination, administration and instruction in connection to Vaccine, Immunization and Vaccination and additionally an expansiveness of different subjects.

 This meeting makes a stage for Policy-creators, Scientists, agents and leaders in Vaccine, Immunization and Vaccination to display their most recent research and find out about all the imperative advancements in Vaccine, Immunization and Vaccination. Real subjects talked about are Latest developed vaccines, Production and effectiveness of vaccines, Types of vaccines, Veterinary vaccines, Paediatric vaccines, Vaccines against drugs, Vaccines and autism, Vaccines for unconventional diseases, Animal and plant derived vaccines, Vaccines safety and efficiency, Current research and future challenges in vaccines, Society and cultural aspects of vaccines.

 Why Attend???

 Vaccines Congress 2018 gives a worldwide stage to trading thoughts and makes us overhauled about the most recent advancements in the field of Vaccine, Immunization and Vaccination. The chance to go to the presentations conveyed by Eminent Scientists from everywhere throughout the world.

· Meet experts and influences face to face.

· Conferences provide a great opportunity to network where most people can help each other uncover ideas and spark inspiration.

·To learn new things in your field

· Conferences Build Your Knowledge Base

· Encounter new vendors and suppliers

· Attending a conference allows you to grow and challenge yourself

· Attending conferences grow your professional network

· Position your company as a champion

· Network with leaders and influencers from the scientific, academic and R&D communities

Welcome Message

Vaccines Congress 2018 extends the heartiest welcome to proficient delegates, scientists, professors, students, young researchers, business executives, scholars, chemists and professionals across the globe to be a part of “World Vaccines and Immunology Congress", during July 23-24, 2018, to be held at Osaka, Japan. Keynote presentations, exhibitions, oral talks and poster presentations outline the key attractions of the conference on the theme "Explore the Intriguing Ideas in the Arena of Vaccines."

Allied Academies  organizes Vaccines Congress 2018 along with 500+ Conferences across USA, Europe & Asia every year with support from 1000 more scientific societies and Publishes 400+ Open access journals which contain over 30000 eminent personalities as editorial board members.

We invite you to join us at the Vaccines Congress 2018, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Vaccines Congress 2018 organizing committee look forward to meeting you in Osaka, Japan.

Sessions and Tracks

Session 1: Vaccines and Vaccination

A vaccine is a biological formation that provides active acquiredimmunity to a particular disease. A vaccine typically contains an agent thatfeatures a disease-causing microorganism and is often made from weakened orkilled forms of the micro-organism, its toxins, or one of its surface proteins.They create immunity against a disease. A Traditional vaccine consists ofagents that resemble the disease- causing organism. When these agents enter thehuman body they stimulate the immune system to recognize these agents asforeign and destroy them. It also makes the immune system remember theseforeign agents so that they can recognize and destroy the real live virulentgerms.  A vaccine can be administered into the body through injections, bymouth or by aerosol.

Following are the issues majorly studied in vaccines.

· VaccineSafety

· Vaccine Work

· Vaccine Type

· VaccineIngredients

Session 2: Types of vaccines 

Depending upon the strategies used to reduce the risk of illness causedby a vaccine, while retaining their ability to induce a beneficial immune responsethey are classified into various types. The human vaccines against viruses weremade using weaker or attenuated viruses whereas a small pox vaccine is made ofcowpox, a poxvirus similar enough to smallpox virus to create immunity. Severaldifferent processes are involved in vaccine production based on which they areclassified into different types. 

• Live attenuated vaccines

Inactivated/ Killed vaccines

Toxoid

• Subunit/ Conjugate

• Heterotypic

Valance

Session 3: Vaccination and Immunisation

A vaccination is the injection of a killed or weakened organism to boostthe immune system’s ability to fight against that organism. Vaccination is asuspension of attenuated or killed microorganisms that are administered forprevention or treatment of infectious disease. The vaccination helps the immunesystem to recognize and fight specific germs. Perfect immunity against adisease is not guaranteed through vaccination. Immunization refers to makingsomeone immune against infections or diseases. Immunization is not only causedby vaccines but there are also some diseases that cause immunization after anindividual encounters and recovers from that disease.

• Active Immunization

• Passive Immunization

• Chickenpox vaccine

• Diphtheria, Tetanus, Pertussis, and Polio vaccine

• Haemophilus influenzae type b vaccine

• Hepatitis B vaccine

• Influenza vaccine

• Measles, Mumps, and Rubella vaccine

• Meningococcal vaccine

• Pneumococcal vaccine

Session 4: Clinical and Vaccine Immunology

Clinical Immunology deals with the study of diseases and disorders thatoccurs as a result of weak immune system which includes aberrant action,failure, and abnormal growth of the cellular elements of the immune system. Italso deals with diseases related to other systems, where immune responses playa role. Vaccine Immunology deals with the study of vaccines and theirimmunological effects. It deals with immunological vaccines, their synthesis,development and therapeutic desirability and compatibility.

Cellular and Humoral immunity

Immuno-epidemiology

• Immunological and Immune-mediated disorders

• Microbial immunology

• Viral immuno-pathogenesis

Session 5: Vaccine Preventable Diseases

An infectious disease for which an effective preventive vaccine existsis termed as a vaccine-preventable disease. If a person dies from a disease forwhich vaccines are available then the death is considered as a vaccine-preventable death. Vaccines produced to fight against bacterial and viraldiseases are a part of controlling communicable disease world-wide. Vaccinationagainst a specific disease reduces the social and economic burden of thedisease on communities apart from reducing the incidence of that disease.

• Diphtheria

• Tetanus

• Pertussis (whooping cough)

• Poliomyelitis (polio)

• Measles

• Mumps

• Rubella

• Haemophilus influenzae type b infections

• Hepatitis B

• Influenza

• Pneumococcal infections

Session 6: Plant based Vaccines

The vaccines in which the desired genes that encode the antigen proteinfor particular disease are inserted into the genome of plant tissue by variousmethods are termed as plant-based vaccine. The most common methods that areused to produce effective plant- based vaccines are Agrobacterium-mediated genetransfer and Transformation via genetically modified plant virus. Howeveradvancements in the field of science and technology developed new approachessuch as agro infiltration, biolistic, electroporation, polyethylene glycoltreatment and sonication to replace the former methods.

• Plant-Based Vaccines Production

• Direct & Indirect Gene Delivery Method

• Immunogen Design and Gene Synthesis

• Methods to Increase the Efficiency of Gene Delivery

• Challenges of Plant-Based Vaccines

• Plastid transformation

Session 7: Oncolytic Virus Immunotherapy

Oncolytic Virus Immunotherapy exemplifies an exciting cancer treatmentwhich stimulates a patient-specific immune response against cancer by makinguse of a virus’ ability to replicate and kill tumour tissue selectively. Immunestimulating chemicals are produced by genetically modifying the OncolyticViruses which also makes them more specific for cancer cells. Therapeuticcancer vaccines and mAb therapy are some of the cancer immunotherapies withwhich Oncolytic virus immunotherapy are often combined. 

• Engineering Oncolytic viruses

• Oncolytic behaviour of wild-type viruses

Tumour cell phenotype

• Inherent tumour physiology

Session 8: Preventive and Therapeutic Cancer Vaccines

The vaccines that prevent an infection which causes cancer arePreventive Cancer Vaccines. Some of the preventive vaccines available includethe HPV and hepatitis B vaccines which prevents cervical, anal, and head andneck cancers. On the other hand the vaccines that trigger the immune system torecognize and destroy certain markers, or antigens, present on or in cancercells are termed as Therapeutic Cancer Vaccines 

• Vector-based vaccines

• Dendritic cell

Antigen vaccines

• Tumour cell vaccines

• DNA Vaccines

• Protein or Peptide Cancer Vaccines

• Allogenic cancer vaccines

• Autologous cancer vaccines

Session 9: Vaccine Adjuvents

Adjuvants are ingredients of a vaccine that creates a stronger immunityin patient’s body by enhancing and directing the adaptive immune response mediated by lymphocytes B and T cells against the antigens. The vaccines workbetter with the help of adjuvants. Naturally occurring adjuvants are present invaccines produced from weakened or dead microorganisms. Adjuvants are used toenhance the immunogenicity of recombinant antigens, to reduce antigen amount,to increase vaccines efficacy and as antigen delivery system for antigen uptakeby mucosa. 

• Mineral salt adjuvants

• Tensoactive adjuvants

• Bacteria-derived adjuvants

• Adjuvant emulsions

• Liposome adjuvants

• Polymeric microsphere adjuvants

• Carbohydrate adjuvants

• Cancer vaccine adjuvants

Session 10: Vaccines Delivery System

Vaccine Delivery System is used to promote uptake of the vaccines with thehelp of absorption enhancers in vaccine formulations. Oral Vaccines are notabledevelopments in vaccine delivery technologies. Oral vaccines have manyadvantages such as no risk of blood contamination; they need not be liquids, assolids they are less prone to damage and spoilage. Lipid-based delivery systemscan be used to achieve needle-free delivery systems. Recent developments invaccine delivery technologies paved way for Single dosage vaccines which aregiven to prevent four to six diseases.  

• Polymers in solid particulate vaccine delivery

• Oral Immunization

• Liposomal delivery systems

• Emulsion delivery systems

• Polymeric nanoparticle delivery systems

• Micellar delivery systems

• Dendrimer-based delivery systems

• Needle-free delivery

Session 11: Biotechnology and Modern Vaccine Technology

Biotechnology is used in the development of vaccine in three differentways: Using a special monoclonal antibody in the separation of pure antigens,using cloned genes for the synthesis of antigens, synthesized proteins used asvaccines. Recombinant vaccines are vaccines produced from recombinant DNATechnology. They are also called as subunit vaccines. It is necessary that themodern biopharmaceutical vaccines are rationally designed with chemical andphysical attributes that distinguish the microbes and creates immune response

• Recombinant vaccines

• Hydrophobic Nanoparticle Technology

• Modern vaccine formulation technologies

• TLR Agonists

• Surfaced Arrayed Therapeutics

• Immunopurification

• Cloned genes

• Synthetic peptides

Session 12: Vaccine Development and Production

Vaccine development involves a combination of public and private and itis a long and complicated process which lasts for around 10- 15 years. Not allvaccines that are designed gets licensed only tiny percentage of candidatevaccine are licensed. This makes the vaccine research and development costshigher. Vaccines are first designed in laboratories and assays are made withanimals before they are tested with humans. The vaccine production cycle isquite different from a pharmaceutical product development since vaccines arebiological products made from microorganisms. The challenging factors whichmakes the vaccine development little complicated includes the identification ofsuitable antigens, delivery methods which are acceptable, adjuvants,difficulties in manufacturing. 

• Exploratory stage

• Pre-clinical development

• Clinical Development

• Clinical Development of Pandemic Vaccines

• Regulatory approval

• Manufacturing process

• Quality control

Session 13: Travel and Edible Vaccines

Travel vaccines are recommended to provide protection against diseasesendemic to the country of origin or of destination. They are intended toprotect travellers and to prevent disease spread within and between countries.There is no single vaccination schedule that fits all travellers. Each schedulemust be individualized according to the traveller’s previous immunizations,health status and risk factors, the countries to be visited, the type andduration of travel, and the amount of time available before departure. Edible vaccines hold great promise as a cost-effective,easy-to-administer, easy-to-store, fail-safe and sociocultural readilyacceptable vaccine delivery system, especially for the poor developingcountries. It involves introduction of selected desired genes into plants andthen inducing these altered plants to manufacture the encoded proteins.

• Development of edible vaccines

• Application of edible vaccines

• Candidates for edible vaccines

• Advantages of edible vaccines

• Pre-travel vaccination and its wider impact

Session 14: Veterinary Vaccines

Considerable progress has been made in the production of veterinary vaccines whether live or inactivated for animal use during the past two decadeswith the increasing use of continuous cell lines as a substrate and adoption ofthe fermenter technology for antigen production. These vaccines are producedfor administration to domestic animals or wild species by parenteral or oralroutes according to vaccine characteristics. More recently a third generationof live veterinary rabies vaccine has been developed using recombinanttechnology. Depending upon the expression system these vaccines are used eitherparentally or orally. Oral rabies vaccines are widely used in foxes in Europeand in racoons in the USA. Trials are under way for the oral immunization ofdogs in developing countries.

• Second-generation veterinary vaccines

• Highly immunogenic inactivated cell culture vaccines

• Third generation of live rabies vaccines

• Live or inactivated veterinary vaccines

• Veterinary vaccines for parenteral use

• Modified live-virus veterinary vaccines for oral immunization ofwildlife

• Recombinant veterinary vaccines for oral immunization of wildlife

Session 15: Geriatric Immunization

As we get older, our immune system tends to weaken over time, putting usat higher risk for certain diseases. This is why, in addition to seasonal flu(influenza) vaccine and Td or Tdap vaccine (tetanus, diphtheria, andpertussis), the adults 60 years or older should take Pneumococcal vaccines,which protect against pneumococcal diseases, including infections in the lungsand bloodstream (also recommended for adults younger than 65 years who havecertain chronic health conditions) and Zoster vaccine, which protects againstshingles.

• Flu shots for seniors

• Immunization schedule for elderly people

• Immunization and its side effects in geriatrics

• Vaccine dosing and administration in older adults

• Herpes zoster vaccines

• Pneumococcal polysaccharide vaccines

• Contraindications and precautions during vaccination ingeriatrics

• Risk factors in geriatric immunization

 Session 16: Current research and future challenges

Vaccine development remains challenging because of the highlysophisticated evasion mechanisms of pathogens for which vaccines are not yetavailable. Recent years have witnessed both successes and failures of novelvaccine design and the strength of iterative approaches is increasinglyappreciated. These combine discovery of novel antigens, adjuvants and vectorsin the preclinical stage with computational analyses of clinical data toaccelerate vaccine design. Reverse and structural vaccinology have revealednovel antigen candidates and molecular immunology has led to the formulation ofpromising adjuvants. Gene expression profiles and immune parameters in patients,vaccines and healthy controls have formed the basis for bio-signatures thatwill provide guidelines for future vaccine design.

• Immunological challenges

• Antigen discovery

• Immunization routes

• Aspects of pathology and host responses

• Expanded testing and modeling of vaccine

• Chloroplast-derived vaccines antigens and therapeutics

• Chloroplast-derived viral antigens

Session 17: Vaccines and Autism

Vaccinations may be one of the triggers for autism. Substantial datademonstrate immune abnormality in many autistic children consistent withimpaired resistance to infection, activation of inflammatory response, andautoimmunity. Impaired resistance may predispose to vaccine injury in autism. Amercurial preservative in childhood Vaccines, thimerosal, may cause directneurotoxic, immune-depressive, and autoimmune injury and contribute toearly-onset and regressed autism. Live viruses in measles, mumps, and rubella(MMR) may result in chronic infection of the gut and trigger regressed autism.Thimerosal injection may potentiate MMR injury.

• Autism-vaccines hypothesis

• Live viruses in measles, mumps, and rubella (MMR)

• Vaccines containing thimerosal

• Simultaneous administration of multiple vaccines

• Autoimmunity in autism

• Depressed resistance in autism

Session 18: Immunization and Bioterrorism

Bioweapons threat could include the deliberate release of a biologicalagent by attackers that causes one or more variety of different diseases. Theuse of effective vaccines would likely to protect lives and limit diseasespread in a biological weapons emergency. Licensed vaccines are currentlyavailable for a few threats, such as anthrax and smallpox, and research isunderway to develop and produce vaccines for other threats, such as tularaemia,Ebola Virus, and Marburg virus. Many bioweapon disease threats, however, lack acorresponding vaccine, and for those that do, significant challenges exist totheir successful use in an emergency situation.

• Anthrax and Smallpox

• Plague and Tularemia

• Ebola, Marburg, Lassa, and Machupo Virus

• Q fever, Ricin toxin, Typhus fever

• Nipah virus

Session 19: Vaccines against Drugs

Drug Addiction is a serious problem worldwide. One therapy beinginvestigated is vaccines against drugs of abuse. The antibodies elicitedagainst the drug can take up the drug and prevent it from reaching the rewardcentres in the brain. Few such vaccines have entered clinical trials, butresearch is going on apace. Many studies are very promising and more clinicaltrials should be coming out in the near future.

• Drug molecules and immune system

• Morphine and heroin vaccines

• Methamphetamine vaccines

• Nicotine vaccines

• Cocaine vaccines

• Hapten structure, linkage chemistry, immunogenic proteins, andadjuvants

Session 20: Paediatric Vaccination

Immunization against diseases such as Polio, Tetanus, Diphtheria, andPertussis saves the lives of approximately three million children each year.Immunization also prevents many more millions from suffering debilitatingillness and lifelong disability. Globally, approximately 132 million babiesneed to be fully immunized each year. In order to meet this need, immunizationsystems must have adequate resources, trained and motivated staff, and amplevaccines and syringe supplies.

• Chickenpox vaccination

• 5-in-1 vaccines

• Pneumococcal or Pneumo Jab (PCV) vaccines

• Rotavirus vaccines

• Serogroup B meningococcal (MenB) vaccines

• Hib/Meningitis C booster vaccines

• MMRvaccines

• 4-in-1pre-school booster

• HPV vaccines(girls only)

Gastro-intestinal vaccination

• Severereactions to foods, insect stings, and medications (anaphylaxis)

• Neonatalrespiratory syncytial virus infection vaccine




 

 

Market Analysis Report

Vaccines are becoming an engine for pharmaceutical industry. Newer and more expensive vaccines are coming into the market faster than ever before. Vaccines have an increasing demand, new target population and larger emerging markets. The vaccines market has very specific features, which increase the intricacy of determining and understanding pricing and procurement. Researches in vaccines are focused on new disease targets and new development strategies. Vaccines development is a complex, expensive, and time-consuming process, typically costing $500 million or more and spanning several years.


Global Vaccine Market:

When compared to the overall market for pharmaceuticals the revenue growth contingency in vaccines looks far more favourable. In 2015 revenues earned by vaccines manufacturers worldwide reached $27.6 billion, up 11% from $24.7 billion in 2014, as sales in all segments expanded. The world vaccines market is envisioned to rise at a compound annual rate of 7.6% during 2013–2022, reaching $45.1 billion in 2022 as new product inventions continue and usage of current products expands. The vaccines market is expected to reach USD 49.27 Billion by 2022 from USD 32.31 Billion in 2016 at a CAGR of 7.5%.


Why Osaka?

Osaka is a large port city and commercial centre on the Japanese island of Honshu. It's known for its modern architecture, nightlife and hearty street food. The 16th-century shogun ate Osaka Castle, which has undergone several restorations, is its main historical landmark. It's surrounded by a moat and park with plum, peach and cherry-blossom trees. Sumiyoshi-taisha is among Japan’s oldest Shinto shrines.

Osaka was evaluated in Research & Development only. Osaka currently markets vaccines in Japan only and is growing its vaccine pipeline, including R&D projects for dengue and chikungunya. Osaka performs above average in Research & Development, and has clear access provisions for its late-stage vaccine candidate. While it does not currently market vaccines in countries in scope, it is taking steps to support affordability and supply of vaccines in its pipeline. For example, from 2016, Osaka has been developing a low-cost IPV with support from the Bill & Melinda Gates Foundation. The beginning stages of early traditions of visits to lovely destinations. Japan's rich history can be experienced most wherever in the country. With numerous old royal residences so far remaining the nation over, it's definitely not hard to set aside a trip back in chance to a place that is known for medieval rulers. The Travel and Tourism Competitiveness Report 2017 positions Japan fourth out of 141 countries for the most part, which was the best in Asia. Japan got for the most part high scores in all viewpoints, especially human services and cleanliness, wellbeing and security, social resources and business travel.

Global Statistics of Vaccines

Global Influenza Vaccine Market will Increase to US$ 5.74 Billion by the Year 2022 – Research and Markets.

The study based on Evaluate Pharm survey shows that at the end of 2013 the sales volume of global vaccine market was $ 25.6 billion and is expected to rise to $41.3 billion by 2020.

 

Associations & Societies Associated with Vaccines in and around Osaka:

•           Japanese Society for Immunology (JSI)

•           The Japanese Society for Vaccinology

•           The Japanese Society of Virology

•           The Japanese Association Of Medical Sciences

•           Japan Society of Immunology and Reproduction

•           Japan Pediatric Society



Organizing Committee
OCM Member
Merita Kucuku
Head of National Regulatory Authority
National Agency for Medicines & Medical Devices
Bucharest, Romania
OCM Member
Tirasak Pasharawipas
Ph.D. from Faculty of Microbiology, Mahidol University, Bangkok.
Graduate School of Medical Technology, Rangsit University
bangkok, Thailand
OCM Member
Ljudmila Stojanovich, MD, PhD, FRCP
Head of Scientific Research Board, Internal medicine-rheumatologist
University of Belgrade
 Beograd, Serbia
OCM Member
Arwa Abdelhalim Mohammed
Doctor Advancement committee Coordinator in Sudan Medical Council
Department of Biotechnology, Africa city of Technology, Sudan
Al-Gamaa Ave, Sudan
OCM Member
Jae-Hwan Nam
senior research scientist at the KNIH , Department of Biology at Korea University
Department of Biotechnology, The Catholic University of Korea
Busan, South Korea
OCM Member
Gerardo Guillén
Director at the Center for Genetic Engineering and Biotechnology
Centro de Ingeniería Genética y Biotecnología, Cuba
Havana, Cuba
OCM Member
María Teresa Sotelo
Member of the National of Health Secretariat Commission for Comprehensive Assistance of Abused Child's, research in various criminal and medical disciplines that delve into the origin of the child abuse and risk factors associated.
President-Fundación En Pantalla Contra la Violencia Infantil, Mexico
Mexico, Mexico
OCM Member
Anouar ABIDI
professor of High Institute of Health and Paramedical Sciences, Tunisia, Faculty of Medicine of Tunis,Laboratory of Physiology.
Laboratory of Physiology, Faculty of Medicine of Tunis, University of Tunis El Manar, La Rabta 1007, Tunis, Tunisia.
Tébessa, Algeria
OCM Member
Mark L. Bagarazzi
Chief Medical Officer at Inovio Pharmaceuticals , directed Worldwide Regulatory Affairs, Vaccines/Biologics at Merck
Inovio Pharmaceuticals,clinical development, biologics manufacturing, regulatory affairs, USA
Auburn, USA
OCM Member
K. M. Yacob
physician in the field of healthcare in the state of Kerala in India
Marma Heatth Centre,Kochi
Calicut, India
OCM Member
Mohd Amin Mir
International Editorial Advisory Board member (Chemistry and Analytical Chemistry) at Cambridge Scholars , Dean of Sciences
Professor in the Department of Chemistry at Uttaranchal University, Premnagar Dehradun
Rishikesh, India
OCM Member
Hamid Yahya. Hussain
Expert Consultant in Public Health Medicine for the World Health Organization and leader of Dubai's Childhood & Adolescent Obesity Management Taskforce., Deputy Director of School Health
Health Affairs Department, Primary Health Care Services Sector, Dubai Health Authority, Dubai, UAE
Riyadh, Saudi Arabia

To Collaborate Scientific Professionals around the World

Conference Date July 23-24, 2018
Speaker Oppurtunity Day 1 Day 2
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Sponsorship Opportunities Click here for Sponsorship Opportunities
Venue
&
Hospitality

Hyatt Regency Osaka,1-13-11 Nanko-Kita, Suminoe-Ku   Osaka, Japan, 559-0034 wall tension.

Register soon to avail the accommodation at the same venue.

Click here for Registration

For Discounts & Group registration

Contact: Adilia Grainger (Program Manager)

vaccinecongress@alliedconferences.org

eurovaccine@alliedmeetings.com          


 

Join The Discussion

Allied Academies Global Conference Directory

Mail us at

Drop us an email for Program enquiry
vaccinecongress@alliedconferences.org
Sponsors/Exhibiting/Advertising
eurovaccine@alliedmeetings.com
Sponsors/Exhibiting/Advertising
vaccinecongress@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com

Authorization Policy



Copyright © 2018-2019 Allied Academies, All Rights Reserved.